New targeted radiation therapy shows promise for Hard-to-Treat cancers
NCT ID NCT07261631
First seen Jan 04, 2026 · Last updated May 13, 2026 · Updated 16 times
Summary
This early-phase study tests a new drug (177Lu-DFC413) that delivers radiation directly to cancer cells in adults with advanced solid tumors like pancreatic, lung, breast, colorectal, and soft tissue cancers. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 180 participants will receive the treatment and be closely monitored for side effects and response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Novartis Investigative Site
RECRUITINGMontreal, Quebec, H3T 1E2, Canada
-
Novartis Investigative Site
RECRUITINGOdense C, 5000, Denmark
-
Novartis Investigative Site
RECRUITINGVandœuvre-lès-Nancy, 54511, France
-
Novartis Investigative Site
RECRUITINGEssen, 45147, Germany
-
Novartis Investigative Site
RECRUITINGHaifa, 3109601, Israel
-
Novartis Investigative Site
RECRUITINGTel Aviv, 6423906, Israel
-
Novartis Investigative Site
RECRUITINGSingapore, 168583, Singapore
Conditions
Explore the condition pages connected to this study.